A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- 26 Feb 2018 According to an Exelixis media release, results from the study were presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium.
- 13 Feb 2018 Results published in the Exelixis media release.
- 13 Feb 2018 According to an American Society for Radiation Oncology media release, data from this study will be presented on February 16 at the 2018 Multidisciplinary Head and Neck Cancers Symposium.